|
| 37975877 | Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug development. | J Natl Cancer Inst | 2024 |
| 37889049 | Childhood cancer data initiative: Status report. | Pediatr Blood Cancer | 2024 |
| 37975877 | Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug development. | J Natl Cancer Inst | 2024 |
| 37889049 | Childhood cancer data initiative: Status report. | Pediatr Blood Cancer | 2024 |
| 36219676 | Fine-Tuning the Relevance of Molecular Targets to Pediatric Cancer: Addressing Additional Layers of Complexity. | Clin Pharmacol Ther | 2023 |
| 36219676 | Fine-Tuning the Relevance of Molecular Targets to Pediatric Cancer: Addressing Additional Layers of Complexity. | Clin Pharmacol Ther | 2023 |
| 37267580 | The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer. | J Clin Oncol | 2023 |
| 37015036 | Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents. | J Clin Oncol | 2023 |
| 36749066 | Clinical trial considerations for pediatric cancer drug development. | J Biopharm Stat | 2023 |
| 37441939 | Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2023 |
| 37171887 | Clinical development of new drugs for adults and children with cancer, 2010-2020. | J Natl Cancer Inst | 2023 |
| 36861410 | <i>KMT2A</i> partner genes in infant acute lymphoblastic leukemia have prognostic significance and correlate with age, white blood cell count, sex, and central nervous system involvement: a Children's Oncology Group P9407 trial study. | Haematologica | 2023 |
| 36600441 | Utility of propensity score-based Bayesian borrowing of external adult data in pediatric trials: A pragmatic evaluation through a case study in acute lymphoblastic leukemia (ALL). | J Biopharm Stat | 2023 |
| 37422730 | Assessing Information Gaps Associated with Initial Pediatric Study Plans for New Oncology Drug and Biological Products. | Clin Pharmacol Ther | 2023 |
| 37349019 | Clinical trials for paediatric cancers under new legislation in the USA. | Lancet Child Adolesc Health | 2023 |
| 37422730 | Assessing Information Gaps Associated with Initial Pediatric Study Plans for New Oncology Drug and Biological Products. | Clin Pharmacol Ther | 2023 |
| 37349019 | Clinical trials for paediatric cancers under new legislation in the USA. | Lancet Child Adolesc Health | 2023 |
| 37015036 | Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents. | J Clin Oncol | 2023 |
| 37441939 | Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2023 |
| 37171887 | Clinical development of new drugs for adults and children with cancer, 2010-2020. | J Natl Cancer Inst | 2023 |
| 37267580 | The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer. | J Clin Oncol | 2023 |
| 36749066 | Clinical trial considerations for pediatric cancer drug development. | J Biopharm Stat | 2023 |
| 36600441 | Utility of propensity score-based Bayesian borrowing of external adult data in pediatric trials: A pragmatic evaluation through a case study in acute lymphoblastic leukemia (ALL). | J Biopharm Stat | 2023 |
| 36861410 | <i>KMT2A</i> partner genes in infant acute lymphoblastic leukemia have prognostic significance and correlate with age, white blood cell count, sex, and central nervous system involvement: a Children's Oncology Group P9407 trial study. | Haematologica | 2023 |
| 34714930 | Recommendations for Dose Selection for Adolescent Patients in Relevant Adult Oncology Clinical Trials. | Clin Pharmacol Ther | 2022 |
| 35947814 | The Critical Role of Academic Clinical Trials in Pediatric Cancer Drug Approvals: Design, Conduct, and Fit for Purpose Data for Positive Regulatory Decisions. | J Clin Oncol | 2022 |
| 35561013 | FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma. | Pediatr Blood Cancer | 2022 |
| 36335782 | Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2022 |
| 36334035 | A mouse pancreatic organoid model to compare PD-L1 blocking antibodies. | MAbs | 2022 |
| 36328007 | ACCELERATE Paediatric Strategy Forums: an advance for oncological drug development? | Lancet Oncol | 2022 |
| 35863108 | Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2022 |
| 36446043 | Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. | JCO Precis Oncol | 2022 |
| 33930159 | Patient-Reported Outcomes in Pediatric Cancer Registration Trials: A US Food and Drug Administration Perspective. | J Natl Cancer Inst | 2022 |
| 35290915 | ACCELERATE - Five years accelerating cancer drug development for children and adolescents. | Eur J Cancer | 2022 |
| 34840026 | Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2022 |
| 34714930 | Recommendations for Dose Selection for Adolescent Patients in Relevant Adult Oncology Clinical Trials. | Clin Pharmacol Ther | 2022 |
| 35561013 | FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma. | Pediatr Blood Cancer | 2022 |
| 36446043 | Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. | JCO Precis Oncol | 2022 |
| 36335782 | Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2022 |
| 36334035 | A mouse pancreatic organoid model to compare PD-L1 blocking antibodies. | MAbs | 2022 |
| 35863108 | Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2022 |
| 36328007 | ACCELERATE Paediatric Strategy Forums: an advance for oncological drug development? | Lancet Oncol | 2022 |
| 35947814 | The Critical Role of Academic Clinical Trials in Pediatric Cancer Drug Approvals: Design, Conduct, and Fit for Purpose Data for Positive Regulatory Decisions. | J Clin Oncol | 2022 |
| 33930159 | Patient-Reported Outcomes in Pediatric Cancer Registration Trials: A US Food and Drug Administration Perspective. | J Natl Cancer Inst | 2022 |
| 35290915 | ACCELERATE - Five years accelerating cancer drug development for children and adolescents. | Eur J Cancer | 2022 |
| 34840026 | Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2022 |
| 33245181 | A review of the experience with pediatric written requests issued for oncology drug products. | Pediatr Blood Cancer | 2021 |
| 33860611 | A global approach to long-term follow-up of targeted and immune-based therapy in childhood and adolescence. | Pediatr Blood Cancer | 2021 |
| 33910935 | The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology. | Clin Cancer Res | 2021 |
| 33751835 | Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. | Cancer Med | 2021 |